Sign in

    Sung Hong

    Research Analyst at BTIG

    Sung Hong's questions to Aldeyra Therapeutics (ALDX) leadership

    Sung Hong's questions to Aldeyra Therapeutics (ALDX) leadership • Q3 2022

    Question

    Sung Hong, on for Thomas Shrader, asked for more detail on Proliferative Vitreoretinopathy (PVR), including which patients represent the initial target market, what is needed to broaden the drug's use, and if a high-risk surgical subset exists.

    Answer

    President and CEO Dr. Todd Brady clarified that the GUARD trial enrolled patients with recurrent retinal detachments and open globe injuries, with risk increasing with recurrence frequency. He highlighted the compelling efficacy and safety data. With no approved drugs and an orphan designation for prevention, he suggested ADX-2191 could be used broadly if approved, potentially even as a preventative measure in high-risk patients before PVR develops, which would be a key part of its clinical adoption.

    Ask Fintool Equity Research AI

    Sung Hong's questions to Aldeyra Therapeutics (ALDX) leadership • Q1 2022

    Question

    Sung Hong of BTIG, LLC asked about the prioritization strategy for ADX-629's multiple indications and potential partnering, as well as the commercialization plan for ADX-2191 in PVR, including sales force structure and potential synergies with the dry eye team.

    Answer

    CEO Dr. Todd Brady explained that Aldeyra would likely prioritize commercializing ADX-629 for orphan indications like minimal change disease and Sjogren-Larsson syndrome, while seeking partners for mass-market indications like chronic cough. For ADX-2191, he stated that while back-office functions would overlap, the sales force would be distinct from the dry eye team, as it would target a different physician population (retinal surgeons) and involve a different sales model (buy-and-bill).

    Ask Fintool Equity Research AI